Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibitionNathalie Jacque, Didier Bouscary, Anne Marie Ronchetti et al.|Blood|2015Cited by 383
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemiaSophie Park, Didier Bouscary, C. Lacombe et al.|Haematologica|2009Cited by 316
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemiaLise Willems, Didier Bouscary, Nathalie Jacque et al.|Blood|2013Cited by 286
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathwaysJérôme Tamburini, Didier Bouscary, Nicolas Chapuis et al.|Blood|2007Cited by 252
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted TherapiesLise Willems, Didier Bouscary, Jérôme Tamburini et al.|Current Oncology Reports|2012Cited by 210